Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Gray zone lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
24 July 2026
2026 Gray zone lymphoma strategy: epidemiology, CD30 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Primary mediastinal B-cell lymphoma Indication Strategy Report 2026: PD-L1, Trials and Deals
24 July 2026
2026 Primary mediastinal B-cell lymphoma strategy: epidemiology, PD-L1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hepatosplenic T-cell lymphoma Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Hepatosplenic T-cell lymphoma strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Angioimmunoblastic T-cell lymphoma Indication Strategy Report 2026: PI3K-delta, Trials and Deals
24 July 2026
2026 Angioimmunoblastic T-cell lymphoma strategy: epidemiology, PI3K-delta biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
ALK-positive anaplastic large cell lymphoma Indication Strategy Report 2026: ALK, Trials and Deals
24 July 2026
2026 ALK-positive anaplastic large cell lymphoma strategy: epidemiology, ALK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Embryonal tumor with multilayered rosettes Indication Strategy Report 2026: C19MC, Trials and Deals
24 July 2026
2026 Embryonal tumor with multilayered rosettes strategy: epidemiology, C19MC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Intracranial germinoma Indication Strategy Report 2026: KIT, Trials and Deals
24 July 2026
2026 Intracranial germinoma strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Pineoblastoma Indication Strategy Report 2026: CRX, Trials and Deals
24 July 2026
2026 Pineoblastoma strategy: epidemiology, CRX biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Diffuse hemispheric glioma H3 G34-mutant Indication Strategy Report 2026: H3F3A, Trials and Deals
24 July 2026
2026 Diffuse hemispheric glioma H3 G34-mutant strategy: epidemiology, H3F3A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Astrocytoma Indication Strategy Report 2026: IDH1, Trials and Deals
24 July 2026
2026 Astrocytoma strategy: epidemiology, IDH1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Oligodendroglioma Indication Strategy Report 2026: IDH1, Trials and Deals
24 July 2026
2026 Oligodendroglioma strategy: epidemiology, IDH1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Leptomeningeal metastasis Indication Strategy Report 2026: HER2, Trials and Deals
24 July 2026
2026 Leptomeningeal metastasis strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.